ZEUS System (Zio Watch) vs Cardiomo

Direct competitors — feature-level head-to-head below. Comparability 85/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
by iRhythm Technologies
VS
by Cardiomo, Inc.

AI Verdict

Both ZEUS System (Zio Watch) and Cardiomo are AI-powered wearable devices for continuous cardiac monitoring, making them direct competitors. While ZEUS System focuses specifically on detecting and characterizing Atrial Fibrillation (AFib) and other arrhythmias for physicians, Cardiomo offers broader vital sign monitoring and real-time alerts for various cardiovascular diseases to both users and caregivers. The choice between them would depend on whether the primary need is specialized AFib analysis for clinical use or a more general heart health monitoring system with immediate alerts.

Choose ZEUS System (Zio Watch) if…

Choose ZEUS System (Zio Watch) if your primary focus is long-term, continuous cardiac monitoring specifically for the detection and characterization of Atrial Fibrillation (AFib) and other complex arrhythmias, requiring high physician agreement on actionable insights. This tool is ideal for clinical settings where detailed, AI-powered analysis of ECG and PPG data over an extended period (up to 14 days) is crucial for diagnosis and treatment planning.

View ZEUS System (Zio Watch) →

Choose Cardiomo if…

Choose Cardiomo if you need a medical-grade wearable for continuous, remote heart health monitoring with a broader focus on detecting various cardiovascular diseases and providing real-time, life-saving alerts to both users and caregivers. This tool is particularly well-suited for proactive patient management, especially in scenarios where immediate notification of vital sign abnormalities and potential cardiovascular events, including fall detection, is a priority.

View Cardiomo →

When choosing between the ZEUS System (Zio Watch) and Cardiomo, physicians should consider their primary monitoring objectives and desired level of detailed cardiac analysis. The ZEUS System, from iRhythm Technologies, is specifically engineered for long-term continuous cardiac monitoring, excelling in the detection and characterization of Atrial Fibrillation (AFib) and other arrhythmias over a period of up to 14 days. Its AI-powered algorithm provides actionable insights and boasts high physician agreement on its clinically actionable reports. This makes it particularly well-suited for cardiologists and family medicine practitioners focused on diagnosing and managing AFib burden.

In contrast, Cardiomo offers a broader approach to remote heart health monitoring with its medical-grade wearable patch, continuously tracking vital signs such as ECG, heart rate, respiration, and skin temperature. While it also utilizes AI for detecting cardiovascular diseases and arrhythmias, its key practical difference lies in its emphasis on real-time alerts and notifications for users and caregivers, alongside features like fall detection. Cardiomo’s focus on immediate alerts and a wider range of vital sign monitoring makes it a strong contender for physicians in geriatrics or internal medicine who prioritize comprehensive, ongoing surveillance and timely intervention for a broader spectrum of cardiovascular concerns, potentially for a more general patient population.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature ZEUS System (Zio Watch) Cardiomo
Pricing Contact vendor Contact for pricing
Deployment Cloud-based system with a wearable device Cloud-based with wearable device and mobile app
FDA Status 1 AI-estimated Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Cardiomo

Cardiomo appears to have a slight edge in usability due to its patch-based design, which may offer more comfort and discretion compared to a wrist-worn watch for continuous wear. Additionally, its waterproof nature allows for use during activities like swimming, enhancing patient convenience.

Clinical Value

ZEUS System (Zio Watch)

The ZEUS System (Zio Watch) has strong clinical validation, with FDA 510(k) clearance specifically for detecting and characterizing AFib, and studies showing high physician agreement (99%) with its reports. While Cardiomo is medical-grade and ISO 13485 certified, its FDA approval status is not explicitly stated as cleared, and detailed clinical validation results are less prominent in the provided information.

Pricing & Value

Tie

Both tools require contacting the vendor for current pricing, making a direct comparison difficult. Cardiomo previously offered a public price, but this is no longer current. Without transparent and comparable pricing, it's not possible to determine which offers better value.

Enterprise Readiness

ZEUS System (Zio Watch)

ZEUS System (Zio Watch) is developed by iRhythm Technologies, a leading digital healthcare solutions company, and was produced in partnership with Verily, an Alphabet precision health company, suggesting a strong foundation for enterprise integration and scalability. Cardiomo has pilot projects and partnerships, but the scale and depth of enterprise readiness are not as clearly articulated as for Tool A.

Innovation

Tie

Both tools demonstrate innovation in continuous cardiac monitoring using AI and wearable technology. ZEUS System leverages a large repository of ECG data for its AI algorithms and focuses on characterizing AFib burden. Cardiomo offers a comprehensive set of vital sign monitoring and real-time alerts, including fall detection, showcasing a broader scope of innovative features.

Support & Docs

ZEUS System (Zio Watch)

iRhythm Technologies provides a dedicated patient support FAQ, clinical resource center with numerous scientific manuscripts, and readily available instructions for use, indicating a robust support and documentation framework. Information regarding Cardiomo's specific support and documentation resources is not as detailed in the provided data.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature ZEUS System (Zio Watch) Cardiomo
Name ZEUS System (Zio Watch) Cardiomo
Company iRhythm Technologies Cardiomo, Inc.
Description FDA-cleared, AI-powered wearable for long-term continuous cardiac monitoring, specifically designed to detect and characterize Atrial Fibrillation (AFib) and other cardiac arrhythmias, providing actionable insights for physicians. A medical-grade wearable device and an AI-powered platform for continuous and remote heart health monitoring, designed to detect cardiovascular diseases and provide timely alerts to users and caregivers.
Key Features (Monitoring) Continuous ECG and PPG data collection; Long-term continuous monitoring for up to 14 days; Detects and characterizes Atrial Fibrillation (AFib) burden Continuous vital sign monitoring (ECG, heart rate, respiration, skin temperature); Long battery life (up to 7-10 days)
Key Features (Alerts/Reporting) AI-powered algorithm for advanced arrhythmia detection and analysis; Clinically actionable reports with high physician agreement (99%); ZioSuiteu00ae portal and provider mobile app for report interpretation and patient management; MyZiou00ae patient app for digital symptom logging, educational content, and reminders AI-powered disease detection (arrhythmias, cardiovascular events); Real-time alerts and notifications; Mobile application (Android and iOS); Fall detection

Videos

Demos, reviews, and walkthroughs featuring ZEUS System (Zio Watch) and Cardiomo.

Loading videos…
Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

The ZEUS System (Zio Watch) is designed as an integrated, prescription-based solution to improve clinician workflows and care pathways, with reports accessible via the ZioSuite portal and mobile app. Cardiomo aims to provide real-time heart health monitoring with an up-to-the-minute data dashboard and alerts, and its AI analyzes data to provide more accurate diagnoses and treatment. While both systems are cloud-based with wearable devices, the specific depth of their EHR integration would require further inquiry, as general EHR integration of patient-generated health data is still evolving.
The ZEUS System's AFib Context Engine (ACE) algorithm has shown interval-level sensitivity of 93.6% and specificity of 99.1% for AFib detection, with the Zio Watch PPG-derived AFib burden estimate being accurate when compared to a Zio XT reference. Cardiomo states its proprietary algorithms are trained to detect arrhythmias and other cardiac events, and it provides 24/7 monitoring to help detect a possible stroke or heart attack within 2 hours.
The Zio Service, which includes the ZEUS System, aims to offer a comprehensive, quality-assured report to manage staff time burden, suggesting an ease of use for physicians. The ZioSuite web portal and mobile app are designed for healthcare professionals to manage clinical workflows, access reports, and interpret them. Cardiomo emphasizes its user-friendly nature, but specific details on physician training and ongoing support quality for either tool would require direct vendor inquiry.
Detailed audit trails are crucial for identifying potential security breaches, investigating incidents, and complying with regulatory requirements. While the general importance of event logging and user authentication for HIPAA compliance in cardiology information systems is recognized, specific audit-trail features for both the ZEUS System and Cardiomo would need to be confirmed directly with each vendor.
For multi-location cardiology practices, an EHR system needs to support consistent clinical standards across sites, allow for per-site workflow configuration, and offer unified billing within a single platform. The cloud-based nature of both the ZEUS System and Cardiomo suggests potential for multi-site deployment, but specific features for managing consistent protocols, user access, and data aggregation across different locations would be important to discuss with each company.

Backers

Who funded each tool's parent company.

AI Tool Finder
AI-powered search. Results may not be comprehensive.